share_log

Wells Fargo Maintains Equal-Weight on Kezar Life Sciences, Lowers Price Target to $2

Benzinga ·  Nov 14, 2023 08:29

Wells Fargo analyst Derek Archila maintains Kezar Life Sciences (NASDAQ:KZR) with a Equal-Weight and lowers the price target from $4 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment